CD8A and hepatocellular carcinoma: We observed more therapeutic effects and survival benefits from LR-DPVB compared to other groups in Trp53KO/MYCOE HCC model which is known to be an immune desert (cold) model with few CD8+ T cell infiltrates and ICB resistance reported in previous studies29 (Fig. 1l–p).